Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers

被引：33

作者：

Rexer, Brent N.

Ghosh, Ritwik

Arteaga, Carlos L. ^{[1
]}

机构：

[1] Vanderbilt Univ, Sch Med, Div Oncol, Dept Med, Nashville, TN 37232 USA

来源：

CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 14期

关键词：

CANCER; MTOR; ACTIVATION;

D O I：

10.1158/1078-0432.CCR-09-0872

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers. (Clin Cancer Res 2009;15(14) July 2009).

引用

页码：4518 / 4520

页数：3

共 50 条

[41] Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition
Kirkpatrick, Donald S.
Bustos, Daisy J.
Dogan, Taner
Chan, Jocelyn
Phu, Lilian
Young, Amy
Friedman, Lori S.
Belvin, Marcia
Song, Qinghua
Bakalarski, Corey E.
Hoeflich, Klaus P.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (48) : 19426 - 19431
[42] MEK inhibition in combination with PI3K/AKT/MTOR is a promising therapeutic in basal bladder cancer.
Apfel, Athena M.
Merrill, Nathan M.
Vandecan, Nathalie M.
Bao, Liwei
Cheng, Xu
Lopez-Barcons, Lluis A.
Day, Kathleen C.
Palmbos, Phillip L.
Day, Mark L.
Udager, Aaron M.
Soellner, Matthew B.
Merajver, Sofia D.
CANCER RESEARCH, 2021, 81 (13)
[43] K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
Hofmann, Irmgard
Weiss, Andreas
Elain, Gaelle
Schwaederle, Maria
Sterker, Dario
Romanet, Vincent
Schmelzle, Tobias
Lai, Albert
Brachmann, Saskia M.
Bentires-Alj, Mohamed
Roberts, Thomas M.
Sellers, William R.
Hofmann, Francesco
Maira, Sauveur-Michel
PLOS ONE, 2012, 7 (08):
[44] Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
H S Kim
M Jung
H N Kang
H Kim
C-W Park
S-M Kim
S J Shin
S H Kim
S G Kim
E K Kim
M R Yun
Z Zheng
K Y Chung
J Greenbowe
S M Ali
T-M Kim
B C Cho
Oncogene, 2017, 36 : 3334 - 3345
[45] Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
Kim, H. S.
Jung, M.
Kang, H. N.
Kim, H.
Park, C-W
Kim, S-M
Shin, S. J.
Kim, S. H.
Kim, S. G.
Kim, E. K.
Yun, M. R.
Zheng, Z.
Chung, K. Y.
Greenbowe, J.
Ali, S. M.
Kim, T-M
Cho, B. C.
ONCOGENE, 2017, 36 (23) : 3334 - 3345
[46] Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support
F E Bertrand
J D Spengemen
J G Shelton
J A McCubrey
Leukemia, 2005, 19 : 98 - 102
[47] OVERCOMING ENDOCRINE THERAPY RESISTANCE DUE TO PI3K/AKT PATHWAY ACTIVATION BY COMBINATIONS OF mTOR, AKT, OR MEK INHIBITORS
Osborne, K.
Fu, X.
Westbrook, T.
Creighton, C.
Hilsenbeck, S.
Schiff, R.
BREAST, 2013, 22 : S2 - S3
[48] Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support
Bertrand, FE
Spengemen, JD
Shelton, JG
McCubrey, JA
LEUKEMIA, 2005, 19 (01) : 98 - 102
[49] Potent Suppression of the Growth of Human Pancreatic Cancer Cells by Combinations of Inhibitors of the PI3K/mTOR and MEK/ERK Pathways
Xu, Qinhong
Soares, Heloisa
Young, Steven H.
Sinnett-Smith, James
Rozengurt, Enrique
GASTROENTEROLOGY, 2016, 150 (04) : S330 - S330
[50] PI3Kα inhibition reduces obesity in mice
Lopez-Guadamillas, Elena
Munoz-Martin, Maribel
Martinez, Sonia
Pastor, Joaquin
Fernandez-Marcos, Pablo J.
Serrano, Manuel
AGING-US, 2016, 8 (11): : 2747 - 2753

← 1 2 3 4 5 →